Latest News

Category: News

See all

First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix’s Breakthrough Kidney Cancer Imaging Agent

Clinical, News,

Telix today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company’s first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma...

Read more

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

Clinical, News,

Telix announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with...

Read more

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Clinical, News,

Telix today announces that the first patient has been dosed in a named patient (early access) program in the Netherlands for its investigational positron emission tomography (PET) imaging agent TLX250-CDx...

Read more

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Clinical, Events, News,

Telix today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative...

Read more

Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

ASX, News,

Telix Group Chief Medical Officer, Dr Colin Hayward, moderated an expert discussion with global key opinion leaders on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody...

Read more

Telix to Host Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

ASX, News,

Telix today advises it will host an investor webcast on Tuesday, 21 November 2023, from 10.15am – 11.15am AEDT (12:15am CET / 6.15pm EST, 20 November). Telix Group Chief Medical Officer,...

Read more

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

ASX, News,

Telix today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based clinical...

Read more

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

ASX, News,

Telix and Paris-based Mauna Kea Technologies, today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance through a strategic €6.0 million (AU$9.6 million) investment to develop new...

Read more

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

ASX, Clinical, News,

Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC)...

Read more

Telix to Present at Jefferies London Healthcare Conference 2023

News,

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference...

Read more